In the BioHarmony Drug Report Database

"Preview" Icon

Dabrafenib

Tafinlar (dabrafenib) is a small molecule pharmaceutical. Dabrafenib was first approved as Tafinlar on 2013-05-29. It is used to treat melanoma in the USA. It has been approved in Europe to treat melanoma. The pharmaceutical is active against serine/threonine-protein kinase B-raf. Tafinlar’s patents are valid until 2033-08-30 (FDA).

 

Trade Name

 

Tafinlar
 

Common Name

 

dabrafenib
 

ChEMBL ID

 

CHEMBL2028663
 

Indication

 

melanoma
 

Drug Class

 

Raf kinase inhibitors

Image (chem structure or protein)

Dabrafenib structure rendering